Occult hepatitis B

Lancet Infectious Diseases

Volumn 2, Issue 8, 2002, Pages 479-486

  Torbenson, Michael ^a   Thomas, David L ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; VIRUS ANTIGEN; VIRUS DNA;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DNA DETERMINATION; ENZYME BLOOD LEVEL; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER CARCINOMA; LIVER FIBROSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROLOGY;

EID: 0036328759     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00345-6     Document Type: Review

References (79)

1. Hepatitis B: Global importance and need for control
2. The risk of transfusion-transmitted infection
3. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study
4. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies
5. Prevention of perinatal hepatitis B through enhanced case management - Connecticut, 1994-95, and the United States, 1994
6. Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection
7. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases
8. Treatment of chronic hepatitis B
9. Management of hepatitis B: 2000 - Summary of a workshop
10. Chronic hepatitis B
11. Detection of hepatitis B virus DNA directly in human serum by a simplified molecular hybridization test: Comparison to HBeAg/anti-HBe status in HBsAg carriers
12. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants
13. Hepatitis B e antigen-negative chronic hepatitis B
14. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B
15. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers
16. Frequent detection of hepatitis B virus X-gene DNA in hepatocellular carcinoma and adjacent liver tissue in hepatitis B surface antigen-negative patients
17. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants
18. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
19. Role of silent hepatitis B virus in chronic hepatitis B surface antigen liver disease
20. Serum hepatitis C virus RNA and hepatitis B virus DNA in non-A, non-B post-transfusional and sporadic chronic hepatitis
21. To kill or to cure: Options in host defense against viral infection
22. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management
23. Clinical expression of 'silent' hepatitis B virus infection in a patient with visceral leishmaniasis
24. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia
25. Occult hepatitis B virus infection and liver disease: Fact or fiction?
26. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"?
27. Mutations of the X region of hepatitis B virus and their clinical implications
28. Occult hepatitis B virus infection
29. Inapparent "wild-type" and "e-minus variant" HBV infection in patients with HCV-related chronic hepatitis
30. Relevance of inapparent co-infection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis
31. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver
32. HCV genotype and "silent" HBV co-infection: Two main risk factors for a more severe liver disease
33. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers
34. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology
35. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus
36. Serologically silent hepatitis B virus co-infection in patients with hepatitis C virus-associated chronic liver disease: Clinical and virological significance
37. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: Probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection
38. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients
39. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen
40. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C
41. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B
42. The impact of previous HBV infection on the course of chronic hepatitis C
43. Hepatitis B virions isolated with antibodies to the pre-S1 domain reveal occult viraemia by PCR in Alaska Native HBV carriers who have seroconverted
44. Hepatitis B virus with X gene mutation is associated with the majority of serologically "silent" non-b, non-c chronic hepatitis
45. HCV HBV coexist in HBsAg-negative patients with HCV viraemia: Possibility of co-infection in these patients must be considered in HBV-high endemic area
46. Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B
47. Comparison of commercial assays for the quantification of HBV DNA load in health care workers: Calibration differences
48. Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients
49. Overt and hidden co-infection with hepatitis B and C viruses in chronic liver disease and porphyria cutanea tarda
50. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection
51. Extrahepatic replication of duck hepatitis B virus: More than expected
52. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients
53. Purpose of quality standards for infectious diseases
54. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma
55. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: A study of a low-endemic area
56. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action
57. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis
58. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
59. Molecular mechanism of viral hepatocarcinogenesis
60. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma
61. HBx gene of hepatitis B virus induces liver cancer in transgenic mice
62. The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: Potential mechanism of hepatitis B virus-induced liver fibrosis
63. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays
64. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver
65. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: Effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways
66. Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues
67. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases
68. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C
69. Detection of hepatitis B virus x transcripts in human hepatocellular carcinoma tissues
70. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas
71. X region deletion variants of hepatitis B virus in surface antigen-negative infections and non-A, non-B hepatitis
72. Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection
73. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B
74. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis
75. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study
76. Transmission of hepatitis B from hepatitis-B-seronegative subjects
77. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: A multivariate analysis in a longitudinal follow-up study
78. Intrahepatic expression of hepatitis B virus antigens: Effect of hepatitis C virus infection
79. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells